acute promyelocytic leucemia presenting during pregnancy. Clin Leukemia ; Cardonick E, Iacobucci A. Use of chemotherapy during. 21 Nov Para la mayoría de los tipos de leucemia mieloide aguda Para pacientes con leucemia promielocítica aguda (APL) que no responden al. Treatment of acute promyelocytic leukemia: A single institution experience. Tratamiento de la leucemia promielocítica aguda. Experiencia de una sola institución.

Author: JoJojin Kajigis
Country: Sweden
Language: English (Spanish)
Genre: Love
Published (Last): 3 April 2004
Pages: 195
PDF File Size: 10.93 Mb
ePub File Size: 16.60 Mb
ISBN: 272-2-85493-597-5
Downloads: 25185
Price: Free* [*Free Regsitration Required]
Uploader: Goltijind

Variations on a theme: Eur J Haematol ; Braz J Med Biol Res. How to cite this article.

Comments 0 Please log in to add your comment. Treatment of acute promyelocytic leukemia: The molecular remission was achieved leucemia promielocitica aguda the administration of ATRA in five patients, whereas in the remaining eight, chemotherapy CT was required to finally achieve it.

Brit J Haematol ; Suppl. Ann Biol Clin ; Investigation of minimal residual disease in acute leukemia. More on geographic hematology: Cellular immunophenotypes in 97 adults with acute leukemia. Role of promyelocytic leukemia PML protein in tumor suppression. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene. Three patients received an autologous peripheral blood stem cell transplantation 4, 6, 9,19 after achieving wguda molecular remission, in two instances during the first CR and in one, during the second CR vide supra.

TOP Related Articles  69 1894ES PDF

¿Qué sucede si la leucemia mieloide aguda (AML) no responde o regresa después del tratamiento?

Blood ; 90 Suppl. N Engl J Med.

ATRA was given until reaching a complete hematological remission, as defined by usual criteria. Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia AML in Spain.


More on geographic hematology: Correspondence and reprint request: Acute promyelocytic leukemia APL is a model of clinical applicability of the knowledge of molecular physiopathology. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia APL do not confer poor prognosis: Assim como nas outras LMAs, sintomas constitucionais como febre, astenia, hiporexia e perda ponderal predominam.

Flow cytometry in the clinical laboratory. The epidemiology of acute promyelocytic leukaemia. High frequency of acute promyelocytic leukemia in Mexican mestizos.


RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Send the link below leucemia promielocitica aguda email or IM Copy.

Please log in to add your comment. Epidemiology and treatment of acute promyelocytic leukemia in Latin America. About the increased frequency of acute promyelocytic leukemia among Latinos: Agudaa more popular or the latest prezis.

High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Acute myeloid leukemia with recurrent genetic abnormalities. Differing from excellent results observed in developed countries, APL mortality in Brazil is still high, despite the wide availability of drugs.


Substantial progress has occurred in the treatment of APL because of improved understanding of the pathophysiology of the disease and identification of a molecular target. In this work a year-old male patient with acute arterial insufficiency leucejia evaluated. J Am Stat Assoc ; Pathogenesis and management of acute promyelocytic leukemia.

Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Clinical features and outcomes of Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Vasco de Quiroga No. Leuk Lymphoma ; Nonparametric estimations from incomplete observations. The Pleistocene Colonization of the New World.

¿Qué sucede si la leucemia mieloide aguda no responde o regresa después del tratamiento?

Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Principles, applications and problems. Acute promyelocytic leukemia as a paradigm for targeted therapy.